Reshad Amini, DO, earned his undergraduate degree in neurobiology from the University of Maryland College Park and graduated medical school from Lake College of Osteopathic Medicine. After completing a residency in Internal Medicine, Dr. Amini completed a fellowship in Nephrology, both at the Medical College of Virginia. Dr. Amini is board certified in Nephrology and is committed to excellence in patient care.  

He has a broad interest in all aspects of nephrological care such as; home dialysis therapies, chronic kidney disease, Nephrotic syndrome, Nephritis, electrolyte disturbances, and pre-and post-kidney transplant care. He also has a special interest, and vast experience, in treating hypertension and hyponatremia.  

He is currently an associate professor at Virginia Commonwealth Osteopathic Medical School. Dr. Amini is currently working to obtain a Master of Business Administration (MBA) from William & Mary’s Mason School of Business.

Dr. Amini has been practicing in the Hampton Roads area since 2009. He serves as a nephrology consult at the following area hospitals, Mary Immaculate Hospital in Newport News, Riverside Regional Medical Center in Newport News, Sentara Careplex Hospital in Hampton, and Sentara Williamsburg Hospital in Williamsburg.

Outside of his practice, Dr. Amini is actively involved with the TPMG administration team. He has served on the Board of Directors from 2015-2020, Chair of Retirement Committee from 2017-2019, Chair of Communication Subcommittee from 2018-2019, and has been a member of the Peer Review Committee from 2019-present.

• Medical Director
  • Fresenius Kidney Care, John Tylor Dialysis Unit, Williamsburg,  VA, 2016 – present
  • Fresenius Kidney Care, Denbigh Joint Venture Dialysis Unit, Newport News, VA, 2015-present
• Medical Advisory Board
  • Fresenius Kidney Care, Eastern VA, 2019 – Present

Clinical Research:

Sub Investigator

• • Protocol D169AC00001 – A Study to Evaluate the Effect of XXX on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease: Randomized, Double-blind, Placebo-controlled, Event-driven, Parallel Group. Phase 3. 2018 to 2020
  • Protocol AKB-6548-CI-0014 – A Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of XXX for the Correction of Anemia in Subjects with Non-Dialysis-Dependent Chronic Kidney Disease. 2018 – Present